سامانه مدیریت نشریات علمی دانشگاه شاهد

Baluchnejadmojarad, Tourandokht, Fahanik-Babaei, Javad, Mehrabi, Soraya, Roghani, Mehrdad. (1402). Determination of Alzheimer’s disease stage based on plasma cis phosphorylated tau biomarker. , 11(1), 17-21. doi: 10.22070/jbcp.2023.18268.1173
Tourandokht Baluchnejadmojarad; Javad Fahanik-Babaei; Soraya Mehrabi; Mehrdad Roghani. "Determination of Alzheimer’s disease stage based on plasma cis phosphorylated tau biomarker". , 11, 1, 1402, 17-21. doi: 10.22070/jbcp.2023.18268.1173
Baluchnejadmojarad, Tourandokht, Fahanik-Babaei, Javad, Mehrabi, Soraya, Roghani, Mehrdad. (1402). 'Determination of Alzheimer’s disease stage based on plasma cis phosphorylated tau biomarker', , 11(1), pp. 17-21. doi: 10.22070/jbcp.2023.18268.1173
Baluchnejadmojarad, Tourandokht, Fahanik-Babaei, Javad, Mehrabi, Soraya, Roghani, Mehrdad. Determination of Alzheimer’s disease stage based on plasma cis phosphorylated tau biomarker. , 1402; 11(1): 17-21. doi: 10.22070/jbcp.2023.18268.1173

Determination of Alzheimer’s disease stage based on plasma cis phosphorylated tau biomarker

Journal of Basic and Clinical Pathophysiology
دوره 11، شماره 1، شهریور 2023، صفحه 17-21    اصل مقاله (411.33 K)
نوع مقاله: Research Paper
شناسه دیجیتال (DOI): 10.22070/jbcp.2023.18268.1173
نویسندگان
Tourandokht Baluchnejadmojarad* 1؛ Javad Fahanik-Babaei2؛ Soraya Mehrabi3؛ Mehrdad Roghani4
1Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2Electrophysiological Research Center, Tehran University of Medical Sciences, Tehran, Iran and Registry Program of Cognitive Deficit and Alzheimer's Disease Information, Tehran Province, Tehran, Iran.
3Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran and Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Science, Tehran, Iran and Cellular and Molecular
4Shahed Univ.
چکیده
Background and Objective: Alzheimer's disease (AD) is the most prevalent cause of dementia globally, with its incidence continuing to increase. Cis phosphorylated tau (Cis p-tau) is postulated as the earliest detectable pathogenic marker in AD and as a novel diagnostic and therapeutic factor. This study was conducted to evaluate stage of AD patients based on plasma level of Cis p-tau.
Materials and Methods: Target population (65-80 years) was chosen from people with AD who visited the neurology clinic of Firouzgar hospital. Selection of cases was according to their medical history and they were divided into control and AD groups at two early and late stages. Individual's cognitive performance was evaluated using Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR) tests besides measurement of plasma level of Cis p-tau.
Results: The results obtained for this study showed that besides significant difference in cognitive indices between control group and two groups of AD patients at early and late stages of the disease, plasma level of Cis p-tau is significantly higher in AD groups (especially in late stage AD group) as compared to the control and healthy group (p<0.05).
Conclusion: It seems that routine measurement of plasma Cis p-tau in AD patients may be of clinical diagnostic value to differentiate AD stages and to evaluate efficacy of used therapies. However, further large-scale research studies are still required to affirm this issue.
کلیدواژه‌ها
Alzheimer’s disease؛ Cis p-tau؛ Dementia؛ Clinical diagnosis
مراجع
  1. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nature Reviews Disease Primers 2021;7(1):33.
  2. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & Dementia 2014;10(6):844-52.
  3. Cummings J, Hahn-Pedersen JH, Eichinger CS, Freeman C, Clark A, Tarazona LRS, et al. Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review. Frontiers in Neurology 2023;14:1208802.
  1. van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia. Nature Aging 2023;3(5):494-505.
  2. Rajasekhar K, Govindaraju T. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. RSC Advances 2018;8(42):23780-804.
  3. Shiravandi A, Yari F, Tofigh N, Kazemi Ashtiani M, Shahpasand K, Ghanian MH, et al. Earlier Detection of Alzheimer's Disease Based on a Novel Biomarker cis P-tau by a Label-Free Electrochemical Immunosensor. Biosensors (Basel) 2022;12(10).
  4. Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. International Journal of Molecular Sciences 2014;15(3):4671-713.
  5. Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules 2016;6(1):6.
  6. Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 2015;523(7561):431-6.
  7. Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G. Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology 2017;35(10):937-53.
  8. Pourhamzeh M, Joghataei MT, Mehrabi S, Ahadi R, Hojjati SMM, Fazli N, et al. The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic. Cellular and Molecular Neurobiology 2021;41(6):1339-54.
  9. Katsumoto A, Takeuchi H, Tanaka F. Tau Pathology in Chronic Traumatic Encephalopathy and Alzheimer's Disease: Similarities and Differences. Frontiers in Neurology 2019;10:980.
  10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98.
  11. Seyedian M, FALAH M, NOUROUZIAN M, NEJAT S, Delavar A, Ghasemzadeh H. Validity of the Farsi version of mini-mental state examination.
  1. Behzad M, Zirak N, Madani GH, Baidoo L, Rezaei A, Karbasi S, et al. CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum. International Journal of Alzheimer's Disease 2023;2023:5336273.
  2. Byrne GJ, Pachana NA, Goncalves DC, Arnold E, King R, Khoo SK. Psychometric properties and health correlates of the Geriatric Anxiety Inventory in Australian community-residing older women. Aging & Mental Health 2010;14(3):247-54.
  3. Chu C, Pan W, Ren Y, Mao P, Yang C, Liu C, et al. Executive function deficits and medial temporal lobe atrophy in late-life depression and Alzheimer's disease: a comparative study. Frontiers in Psychiatry 2023;14:1243894.
  4. Bolós M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. Biomolecular Concepts 2017;8(1):37-43.
  5. Gaitán JM, Asthana S, Carlsson CM, Engelman CD, Johnson SC, Sager MA, et al. Circulating Klotho Is Higher in Cerebrospinal Fluid than Serum and Elevated Among KLOTHO Heterozygotes in a Cohort with Risk for Alzheimer's Disease. Journal of Alzheimer's Disease 2022;90(4):1557-69.
  6. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's Disease: Past, Present, and Future. Journal of the International Neuropsychological Society 2017;23(9-10):818-31.
  7. Suzuki K, Iwata A, Iwatsubo T. The past, present, and future of disease-modifying therapies for Alzheimer's disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences 2017;93(10):757-71.
  8. Kocahan S, Doğan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clinical Psychopharmacology and Neuroscience 2017;15(1):1-8.
  9. Fišar Z. Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. Biomolecules 2022;12(11).
  10. Cummings JL, Osse AML, Kinney JW. Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification. Drugs 2023, in press.
  1. Dave BP, Shah YB, Maheshwari KG, Mansuri KA, Prajapati BS, Postwala HI, et al. Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development. Cellular and Molecular Neurobiology 2023, in press.
  2. Singh YP, Kumar N, Chauhan BS, Garg P. Carbamate as a potential anti-Alzheimer's pharmacophore: A review. Drug Development Research 2023, in press.
  3. Fung TY, Iyaswamy A, Sreenivasmurthy SG, Krishnamoorthi S, Guan XJ, Zhu Z, et al. Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer's Disease: A Review. Biomedicines 2022;10(3).
  4. Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, et al. New Insights Into the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology 2019;10:1312.
  5. Lamontagne-Kam D, Ulfat AK, Hervé V, Vu TM, Brouillette J. Implication of tau propagation on neurodegeneration in Alzheimer's disease. Frontiers in Neuroscience 2023;17:1219299.
  6. Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications. Molecular Neurodegeneration 2023;18(1):18.
  7. Zetterberg H. Blood-based biomarkers for Alzheimer's disease-An update. Journal of Neuroscience Methods 2019;319:2-6.
  8. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 2018;554(7691):249-54.
آمار
تعداد مشاهده مقاله: 202
تعداد دریافت فایل اصل مقاله: 199